GET DAILY SIGNALSInteger Holdings (ITGR) Prepares for Its Final Public Earnings Report Before KKR Takeover
Key Takeaways
- Integer Holdings is set to release third-quarter 2026 results on Thursday, October 22, marking what appears to be its last earnings update as a public company.
- Wall Street expects adjusted EPS of $1.69 on revenue near $457.8 million.
- The consensus calls for a year-over-year revenue drop of roughly 2.1% and an adjusted EPS decline of about 5.6%.
- Sequentially, revenue is projected to ease about 1% from the second quarter’s $464 million, while EPS should show modest improvement.
- Due to the pending acquisition, the company has pulled its full-year guidance and will not hold an earnings conference call.
- Stockholders approved the KKR merger on October 21, and shares trade near $126.70, just under the $127 per-share deal price.
Why This Report Carries Extra Weight
Integer Holdings Corporation stands as one of the largest medical device outsource manufacturers, supporting the cardio and vascular, cardiac rhythm management, and neuromodulation sectors through its contract development and manufacturing organization model. This quarter takes on added significance as it is likely the final public update before the company transitions to private ownership. In August, an affiliate of KKR-managed funds reached an agreement to buy Integer for $127 per share in cash, representing an enterprise value of roughly $5.7 billion. With the transaction targeted to close by the end of 2026, the focus shifts from ongoing performance to confirming stability during the ownership change.
Quarterly Projections in Detail
Analysts anticipate adjusted EPS of $1.69 alongside revenue of approximately $457.83 million for the third quarter ended in September. The outlook points to a slight sequential profit gain but a modest sales dip from the second quarter’s $464 million. Year over year, revenue is expected to decline about 2.1%, while adjusted EPS should fall roughly 5.6%. Projections have remained steady in recent weeks and months, indicating limited revision risk. I also checked this using Tickeron’s AI Screener to compare the setup against peers in the sector.
Attention will center on margins as well. The trailing twelve-month gross profit margin stands near 26.13%, and any sequential lift would support views on earnings quality amid softer revenue. In the second quarter, Integer delivered adjusted EPS of $1.60 against a consensus near $1.51, with revenue of $464 million slightly exceeding forecasts. Those results provided some reassurance on business steadiness ahead of the ownership shift, even as the company withdrew its outlook and canceled its call after the buyout announcement.
How the Market Is Pricing the Deal
Investor focus ahead of the report centers more on the pending transaction than on day-to-day operations. Shares sit near $126.70, essentially at the $127 cash offer and just below the 52-week high of $126.83. Nine analysts maintain a hold rating, with a consensus price target around $121.80—roughly 4% below the current price and well under the deal level. This reflects expectations that the KKR acquisition will proceed rather than any standalone growth forecast. Because the merger price limits upside, typical earnings volatility should remain contained. The main risks now involve the deal itself, including several stockholder lawsuits and demand letters challenging the proxy. Any updates on timeline, closing conditions, or regulatory status will likely draw more scrutiny than the headline figures.
What to Watch Going Forward
The key near-term driver remains the KKR transaction closing, now expected by year-end following the stockholder vote and resolution of the antitrust waiting period. With the $127 cash price serving as the practical ceiling, attention turns to procedural steps and any lingering litigation. Operationally, the cardiac and vascular segments will be monitored for momentum through the transition. Sequential revenue is forecast to decline about 1%, and commentary on electrophysiology and neuromodulation demand could clarify whether prior product headwinds are easing. Margin trends also matter. The projected sequential EPS rise despite lower revenue hints at efficiency gains and favorable product mix. A gross margin near or above the trailing twelve-month level of about 26% would bolster that perspective. With full-year guidance withdrawn and no conference call planned, the earnings release and future regulatory filings on the merger will supply most of the remaining details for investors.
Using AI Tools for Broader Context
When following situations like this across the medical device space, I find Tickeron’s AI Screener helpful for quickly filtering securities by industry, technical patterns, fundamentals, and performance metrics. It surfaces relevant ideas and helps maintain perspective on how Integer fits within the wider group of healthcare names reporting around the same time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ITGR turns positive, indicating new upward trend
ITGR saw its Momentum Indicator move above the 0 level on September 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 78 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where ITGR advanced for three days, in 227 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 156 of 229 cases where ITGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for ITGR moved out of overbought territory on October 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 21 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 63 cases where ITGR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ITGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
ITGR broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ITGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ITGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.506) is normal, around the industry mean (2.923). P/E Ratio (34.151) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (2.806) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.382) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices and components
Industry MedicalNursingServices
Advertisement